Am J Clin Pathol

1. TAKEDA K, Tang H, Kumar D, Adeniran AJ, et al
   Clinicopathologic characteristics of lymphoproliferative disorders involving the kidney.
   Am J Clin Pathol. 2025;164:192-199.
   

   >> Share

   
   

   
   Am J Hematol

2. OTHMAN T, Baird JH, Wang Y, Pak S, et al
   Outpatient Brexucabtagene Autoleucel in B-Cell Acute Lymphoblastic Leukemia and Mantle Cell Lymphoma.
   Am J Hematol. 2025 Aug 20. doi: 10.1002/ajh.70038.
   

   >> Share

   
   

   
   Blood

3. SCHERER F
   Cracking the POD24 code in follicular lymphoma.
   Blood. 2025;146:899-900.
   

   >> Share

   
   
4. 
   Allo-HCT in Hodgkin lymphoma after CPI.
   Blood. 2025;146:1030.
   

   >> Share

   
   
5. XU P, Zhu Y, Shi ZY, Wang L, et al
   A phase 2 study of zanubrutinib in combination with rituximab and lenalidomide in de novo diffuse large B-cell lymphoma.
   Blood. 2025 Aug 19:blood.2025028649. doi: 10.1182/blood.2025028649.
   

   >> Share

   
   
6. REJESKI K, Sanz J, Fei T, Nair MS, et al
   T-ICAHT: grading and prognostic impact of thrombocytopenia after CAR T-cell therapy.
   Blood. 2025;146:834-846.
   

   >> Share

   
   

   
   BMC Cancer

7. HEROLD S, Schmidt C, Visco C, Tilch MK, et al
   The MCL elderly III trial protocol: an international, randomized, open-label phase II trial to investigate the combinations of venetoclax, ibrutinib and rituximab or bendamustine, ibrutinib and rituximab in patients with treatment naive mantle cell ly
   BMC Cancer. 2025;25:1370.
   

   >> Share

   
   
8. AL-MANSOUR M, Alghanmi HA, Shareef DE, Alshamat ES, et al
   Treatment patterns and survival outcomes of peripheral T-Cell lymphoma in Saudi Arabia: a 12-Year retrospective analysis.
   BMC Cancer. 2025;25:1361.
   

   >> Share

   
   
9. GAO L, Wang L, Xue C, Cen X, et al
   Peripheral EBV antigen-specific T cell is dysfunctional in Epstein-Barr virus positive diffuse large B-cell lymphoma.
   BMC Cancer. 2025;25:1318.
   

   >> Share

   
   

   
   Bone Marrow Transplant

10. DONG Y, Yang T, Zhao M, Song F, et al
    Safety and efficacy of autologous humanized CD19 CAR-T cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma.
    Bone Marrow Transplant. 2025 Aug 20. doi: 10.1038/s41409-025-02691.
    

    >> Share

    
    

    
    Br J Dermatol

11. DOELEMAN T, Beljaards ESM, Ottevanger R, Jansen P, et al
    Added value of pathology consultations in cutaneous lymphomas: a 2-year review from the Dutch national referral and expertise centre.
    Br J Dermatol. 2025 May 14:ljaf184. doi: 10.1093.
    

    >> Share

    
    
12. HODAK E, Amitay-Laish I, Bagot M, Battistella M, et al
    ISCL/EORTC-CLTG/USCLC recommendations for the diagnosis, staging and treatment of early-stage paediatric mycosis fungoides: a modified Delphi consensus. Part one: diagnosis and staging.
    Br J Dermatol. 2025;193:405-414.
    

    >> Share

    
    

    
    Br J Haematol

13. YU F, Yu X, Hu X, Jiang E, et al
    Comprehensive risk stratification for adult T-cell lymphoblastic lymphoma undergoing allogeneic haematopoietic stem cell transplantation.
    Br J Haematol. 2025 Aug 26. doi: 10.1111/bjh.70102.
    

    >> Share

    
    
14. KOCA O, Eskazan AE
    Refining the risk stratification in advanced-stage classical Hodgkin lymphoma: A critical analysis of clinical prediction models.
    Br J Haematol. 2025 Aug 22. doi: 10.1111/bjh.70115.
    

    >> Share

    
    

    
    Haematologica

15. MOLLA R, Bantilan K, Berman E, Caron P, et al
    Two decades of single-institution data reveal rare long-term survivors of relapsed/refractory Burkitt lymphoma.
    Haematologica. 2025 Aug 7. doi: 10.3324/haematol.2024.287165.
    

    >> Share

    
    

    
    J Am Acad Dermatol

16. PANG Y, Thomas ZO, Ayanruoh LD, Enriquez GH, et al
    Skin microbiota differs between Black and White patients with cutaneous T-cell lymphoma.
    J Am Acad Dermatol. 2025 Aug 22:S0190-9622(25)02675.
    

    >> Share

    
    

    
    Leuk Lymphoma

17. CHUMNUMSIRIWATH P, Vittayawacharin P, Pinter-Brown L, Brem EA, et al
    Lite-BEAM expands autologous stem cell transplantation access for older or unfit patients with lymphoma.
    Leuk Lymphoma. 2025 Aug 21:1-5. doi: 10.1080/10428194.2025.2547985.
    

    >> Share

    
    
18. ISKIERKA-JAZDZEWSKA E, Kim WS, Cho SG, Kim TM, et al
    Patient-reported outcomes in relapsed/refractory diffuse large B-cell lymphoma with odronextamab monotherapy.
    Leuk Lymphoma. 2025 Aug 20:1-12. doi: 10.1080/10428194.2025.2535694.
    

    >> Share

    
    
19. MATARASSO GREENFELD S, Dmitrienko S, Shrier I, Deschenes JL, et al
    Understanding the clinical approach to "pathologically ambiguous follicular lymphoma" through a Real-World cohort.
    Leuk Lymphoma. 2025 Aug 18:1-4. doi: 10.1080/10428194.2025.2542943.
    

    >> Share

    
    

    
    N Engl J Med

20. ALEMAN A, Van Oekelen O, Melnekoff DT, Grossman L, et al
    Targeted Therapy of CAR+ T-Cell Lymphoma after Anti-BCMA CAR T-Cell Therapy.
    N Engl J Med. 2025;393:823-825.
    

    >> Share

    
    

    
    PLoS One

21. XU L, Tu G, Cai Z, Lan T, et al
    Predicting in-hospital mortality in ICU patients with lymphoma using machine learning models.
    PLoS One. 2025;20:e0330197.
    

    >> Share

    
    
22. ERDOGAN MS
    On nonparametric estimating ROC curve based on non-uniform rational B-spline.
    PLoS One. 2025;20:e0330175.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share